Company news

Axogen, Inc. news in 2024

Axogen, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

November 6, 2024

Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024

October 23, 2024

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

September 5, 2024

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

September 2, 2024

Axogen, Inc. Reports Second Quarter 2024 Financial Results

August 7, 2024

Axogen, Inc. Announces New Leadership Appointments

August 7, 2024

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

July 22, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

June 30, 2024

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

June 23, 2024

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 27, 2024

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

May 15, 2024

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

May 13, 2024

Axogen, Inc Reports First Quarter 2024 Financial Results

May 1, 2024

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

April 28, 2024

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 15, 2024

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

March 4, 2024

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

February 12, 2024

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 1, 2024

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

January 17, 2024

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

January 3, 2024

Axogen Announces Promotions on Research and Development Team

January 3, 2024

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

January 3, 2024

Calls in 2024

Decks in 2024